Aster Insights
Melissa Mitchell has a diverse work experience in various roles and companies. Melissa started their career as a Clinical Research Associate at Florida Orthopaedic Institute-FORE in 2004 and later became a Clinical Trials Coordinator at H. Lee Moffitt Cancer Center and Research Institute in 2007. In 2008, they joined Aster Insights as a Biorepository Projects Coordinator and later took on the role of Manager, Business Development and Alliance Management. Melissa continued to grow in the company and served as the Director of Strategic Partnerships and, most recently, as the Director of Strategic Alliances. In addition to their work at Aster Insights, Melissa Mitchell served in leadership positions at the Healthcare Businesswomen's Association-Florida Chapter, including President Elect in 2016 and President in 2017.
Melissa Mitchell's education history includes attending the University of South Florida, where they did not declare a specific degree or field of study.
Aster Insights
We believe that personalized medicine starts with a complete view of an individual across their lifetime. Our company was founded in 2006 on the unique principle that informed consent from patients entrusting us with a lifetime connection to their health information, paired with deep partnerships across academia and the life sciences industry, would unlock critical advances in curing cancer. Aster Insights leads the Oncology Research Information Exchange Network (ORIEN®), a consortium of the nation’s leading academic cancer centers that conduct Total Cancer Care®, the world’s largest and longest running observational research study in oncology. TCC® serves as the foundation for novel insights that power oncology breakthroughs. As a long-time innovator in oncology, Aster Insights has world-class expertise in accelerating the life cycle of oncology medical product development. Our solutions are based on scientific and clinical intelligence and strengthened by our unique partnership with patients, academia, and industry. We empower our partners to uncover new targets and biomarkers, enhance cancer detection, deepen our understanding of new treatments, discover new indications, and accelerate clinical trials. Together, we are changing the way cancer is studied, treated, and prevented.